NEWS SOURCE: Epeius Biotechnologies Corporation
LOS ANGELES, Calif. – July 15 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation (www.epeiusbiotech.com), announced today that a Phase I clinical trial has opened at Mayo Clinic Cancer Center, Rochester, Minnesota to test the safety of Rexin-G(TM), the first tumor-targeted gene therapy vector to gain Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The clinical protocol has passed the rigorous reviews of the FDA, the NIH/Recombinant Advisory Committee, and the Institutional Review Board of Mayo Clinic.
A maximum of 24 eligible patients will be entered into the study. Interested persons may call Mayo Clinic Cancer Center at Tel. No.: 507-538-7623 to determine eligibility and potential participation in the study.
ABOUT THE REXIN-G CLINICAL TRIAL:
This is a dose-seeking study that will test the safety of increasing doses of Rexin-G(TM), given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy. Rexin-G(TM) is a tumor-targeted gene therapy vector that contains a “killer” gene that blocks the action of the human cyclin G1 gene. Cyclin G1 is a cell cycle control element that plays an important role in cancer cell growth. When injected into a vein, the Rexin-G(TM) vector seeks out and accumulates in cancerous tumors, therefore, increasing the concentration of the drug in the cancerous tumors and not in normal neighboring organs.
ABOUT EPEIUS:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company that was formed to develop and commercialize the first truly effective Targeted Gene Delivery System (TDS) that can be injected directly into a vein to deliver genetic medicine preferentially to cancerous tumors that have spread throughout the body (metastatic cancer).
Recently, Epeius was granted the approval to provide “Expanded Access to Rexin-G(TM)” by the Philippine Bureau of Food and Drugs for pancreatic and breast cancer. This means that Rexin-G(TM) is now available on a limited commercial basis for the treatment of pancreatic and breast cancer in Manila, Philippines.
More information: www.epeiusbiotech.com.
Rexin-G is a trademark of Epeius Biotechnologies Corporation
News issued by: Epeius Biotechnologies Corporation
# # #
Original Story ID: (575) :: 2005-07-0715-002
Original Keywords: Epeius Biotechnologies Corporation, Clinical Trial For Pancreatic Cancer, Rexin-G, Mayo Clinic, Tumor-Targeted Gene Therapy Vector, rexin g, human cyclin G1 gene, cancer cell growth, Targeted Gene Delivery System, TDS, Cyclin G1, NIH/Recombinant Advisory Committee, Institutional Review Board of Mayo Clinic, Los Angeles, California, Orphan Drug designation, FDA, Mayo Clinic Cancer Center Epeius Biotechnologies Corporation
NEWS SOURCE: Epeius Biotechnologies Corporation | Published: 2005-07-15 12:03:00
IMPORTANT NOTICE FOR ARCHIVAL CONTENT ABOVE: The above archival press release content was issued on behalf of the noted "news source" who provided the content (text and image[s]) and is solely responsible for its accuracy. Links may not work if very old; use such with caution. Send2Press does not represent the "news source" in any capacity. For questions about this content contact the company/person mentioned directly. To report fraud or illegal material, or DMCA complaints, please contact Send2Press via our main site (any such complaints must be made in writing, not by phone).
